The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Cancer Drugs-Global Market Insights and Sales Trends 2025

Cancer Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1829023

No of Pages : 123

Ask Your Query
Synopsis
It is used in the treatment of cancer.
The global Cancer Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Drugs in various end use industries. The expanding demands from the Blood Cancer, Breast Cancer, Gastrointestinal Cancer and Prostate Cancer, are propelling Cancer Drugs market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Drugs covered in this report include Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda and Eli Lilly, etc.
The global Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co.
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Merck KGaA
Ipsen
AbbVie
Gilead Sciences
Global Cancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Drugs market, Segment by Type:
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
Global Cancer Drugs market, by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Cancer Drugs Market Overview
1.1 Cancer Drugs Product Overview
1.2 Cancer Drugs Market Segment by Type
1.2.1 Chemotherapy
1.2.2 Targeted Therapy
1.2.3 Immunotherapy
1.2.4 Hormonal Therapy (Biologic Therapy)
1.2.5 Others
1.3 Global Cancer Drugs Market Size by Type
1.3.1 Global Cancer Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Cancer Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Cancer Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Cancer Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Cancer Drugs Sales Breakdown by Type (2018-2023)
2 Global Cancer Drugs Market Competition by Company
2.1 Global Top Players by Cancer Drugs Sales (2018-2023)
2.2 Global Top Players by Cancer Drugs Revenue (2018-2023)
2.3 Global Top Players by Cancer Drugs Price (2018-2023)
2.4 Global Top Manufacturers Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cancer Drugs Market Competitive Situation and Trends
2.5.1 Cancer Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Cancer Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Cancer Drugs Market
2.8 Key Manufacturers Cancer Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cancer Drugs Status and Outlook by Region
3.1 Global Cancer Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Cancer Drugs Historic Market Size by Region
3.2.1 Global Cancer Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Cancer Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Cancer Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Cancer Drugs Forecasted Market Size by Region
3.3.1 Global Cancer Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Cancer Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Cancer Drugs by Application
4.1 Cancer Drugs Market Segment by Application
4.1.1 Blood Cancer
4.1.2 Breast Cancer
4.1.3 Gastrointestinal Cancer
4.1.4 Prostate Cancer
4.1.5 Respiratory/Lung Cancer
4.1.6 Other Cancers
4.2 Global Cancer Drugs Market Size by Application
4.2.1 Global Cancer Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Cancer Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Cancer Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Cancer Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Cancer Drugs Sales Breakdown by Application (2018-2023)
5 North America Cancer Drugs by Country
5.1 North America Cancer Drugs Historic Market Size by Country
5.1.1 North America Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Cancer Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Cancer Drugs Sales in Value by Country (2018-2023)
5.2 North America Cancer Drugs Forecasted Market Size by Country
5.2.1 North America Cancer Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Cancer Drugs Sales in Value by Country (2024-2029)
6 Europe Cancer Drugs by Country
6.1 Europe Cancer Drugs Historic Market Size by Country
6.1.1 Europe Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Cancer Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Cancer Drugs Sales in Value by Country (2018-2023)
6.2 Europe Cancer Drugs Forecasted Market Size by Country
6.2.1 Europe Cancer Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Cancer Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Cancer Drugs by Region
7.1 Asia-Pacific Cancer Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Cancer Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Cancer Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Cancer Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Cancer Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Cancer Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Cancer Drugs Sales in Value by Region (2024-2029)
8 Latin America Cancer Drugs by Country
8.1 Latin America Cancer Drugs Historic Market Size by Country
8.1.1 Latin America Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Cancer Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Cancer Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Cancer Drugs Forecasted Market Size by Country
8.2.1 Latin America Cancer Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Cancer Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Cancer Drugs by Country
9.1 Middle East and Africa Cancer Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Cancer Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Cancer Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Cancer Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Cancer Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Cancer Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Roche
10.1.1 Roche Company Information
10.1.2 Roche Introduction and Business Overview
10.1.3 Roche Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Roche Cancer Drugs Products Offered
10.1.5 Roche Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis Cancer Drugs Products Offered
10.2.5 Novartis Recent Development
10.3 Celgene
10.3.1 Celgene Company Information
10.3.2 Celgene Introduction and Business Overview
10.3.3 Celgene Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Celgene Cancer Drugs Products Offered
10.3.5 Celgene Recent Development
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Company Information
10.4.2 Bristol-Myers Squibb Introduction and Business Overview
10.4.3 Bristol-Myers Squibb Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Bristol-Myers Squibb Cancer Drugs Products Offered
10.4.5 Bristol-Myers Squibb Recent Development
10.5 Amgen
10.5.1 Amgen Company Information
10.5.2 Amgen Introduction and Business Overview
10.5.3 Amgen Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Amgen Cancer Drugs Products Offered
10.5.5 Amgen Recent Development
10.6 Johnson & Johnson
10.6.1 Johnson & Johnson Company Information
10.6.2 Johnson & Johnson Introduction and Business Overview
10.6.3 Johnson & Johnson Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Johnson & Johnson Cancer Drugs Products Offered
10.6.5 Johnson & Johnson Recent Development
10.7 Pfizer
10.7.1 Pfizer Company Information
10.7.2 Pfizer Introduction and Business Overview
10.7.3 Pfizer Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Pfizer Cancer Drugs Products Offered
10.7.5 Pfizer Recent Development
10.8 Takeda
10.8.1 Takeda Company Information
10.8.2 Takeda Introduction and Business Overview
10.8.3 Takeda Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Takeda Cancer Drugs Products Offered
10.8.5 Takeda Recent Development
10.9 Eli Lilly
10.9.1 Eli Lilly Company Information
10.9.2 Eli Lilly Introduction and Business Overview
10.9.3 Eli Lilly Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Eli Lilly Cancer Drugs Products Offered
10.9.5 Eli Lilly Recent Development
10.10 AstraZeneca
10.10.1 AstraZeneca Company Information
10.10.2 AstraZeneca Introduction and Business Overview
10.10.3 AstraZeneca Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 AstraZeneca Cancer Drugs Products Offered
10.10.5 AstraZeneca Recent Development
10.11 Astellas
10.11.1 Astellas Company Information
10.11.2 Astellas Introduction and Business Overview
10.11.3 Astellas Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Astellas Cancer Drugs Products Offered
10.11.5 Astellas Recent Development
10.12 Merck & Co.
10.12.1 Merck & Co. Company Information
10.12.2 Merck & Co. Introduction and Business Overview
10.12.3 Merck & Co. Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Merck & Co. Cancer Drugs Products Offered
10.12.5 Merck & Co. Recent Development
10.13 Sanofi
10.13.1 Sanofi Company Information
10.13.2 Sanofi Introduction and Business Overview
10.13.3 Sanofi Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Sanofi Cancer Drugs Products Offered
10.13.5 Sanofi Recent Development
10.14 Bayer
10.14.1 Bayer Company Information
10.14.2 Bayer Introduction and Business Overview
10.14.3 Bayer Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Bayer Cancer Drugs Products Offered
10.14.5 Bayer Recent Development
10.15 Biogen Idec
10.15.1 Biogen Idec Company Information
10.15.2 Biogen Idec Introduction and Business Overview
10.15.3 Biogen Idec Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Biogen Idec Cancer Drugs Products Offered
10.15.5 Biogen Idec Recent Development
10.16 Eisai
10.16.1 Eisai Company Information
10.16.2 Eisai Introduction and Business Overview
10.16.3 Eisai Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Eisai Cancer Drugs Products Offered
10.16.5 Eisai Recent Development
10.17 Teva
10.17.1 Teva Company Information
10.17.2 Teva Introduction and Business Overview
10.17.3 Teva Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Teva Cancer Drugs Products Offered
10.17.5 Teva Recent Development
10.18 Otsuka
10.18.1 Otsuka Company Information
10.18.2 Otsuka Introduction and Business Overview
10.18.3 Otsuka Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Otsuka Cancer Drugs Products Offered
10.18.5 Otsuka Recent Development
10.19 Merck KGaA
10.19.1 Merck KGaA Company Information
10.19.2 Merck KGaA Introduction and Business Overview
10.19.3 Merck KGaA Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.19.4 Merck KGaA Cancer Drugs Products Offered
10.19.5 Merck KGaA Recent Development
10.20 Ipsen
10.20.1 Ipsen Company Information
10.20.2 Ipsen Introduction and Business Overview
10.20.3 Ipsen Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.20.4 Ipsen Cancer Drugs Products Offered
10.20.5 Ipsen Recent Development
10.21 AbbVie
10.21.1 AbbVie Company Information
10.21.2 AbbVie Introduction and Business Overview
10.21.3 AbbVie Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.21.4 AbbVie Cancer Drugs Products Offered
10.21.5 AbbVie Recent Development
10.22 Gilead Sciences
10.22.1 Gilead Sciences Company Information
10.22.2 Gilead Sciences Introduction and Business Overview
10.22.3 Gilead Sciences Cancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.22.4 Gilead Sciences Cancer Drugs Products Offered
10.22.5 Gilead Sciences Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cancer Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cancer Drugs Industrial Chain Analysis
11.4 Cancer Drugs Market Dynamics
11.4.1 Cancer Drugs Industry Trends
11.4.2 Cancer Drugs Market Drivers
11.4.3 Cancer Drugs Market Challenges
11.4.4 Cancer Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cancer Drugs Distributors
12.3 Cancer Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock